{
    "clinical_study": {
        "@rank": "75514", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective, multicenter, observational study will assess the prevalence of chronic\n      hepatitis D in patients with chronic hepatitis B in Romania and evaluate the efficacy of\n      Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis D. Eligible patients\n      treated with Pegasys according to current medical practice will be followed until 24 weeks\n      after the end of treatment."
        }, 
        "brief_title": "An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis D, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis D", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis D, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For epidemiological part of the study:\n\n          -  Adult patients >/= 18 years of age\n\n          -  Positive HBsAg for at least 6 months\n\n        For the non-interventional section of the study\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Positive HBsAg for at least 6 months\n\n          -  Positive anti-delta and positive HDV RNA by PCR\n\n          -  Elevated serum ALT >/= 2x ULN\n\n        Exclusion Criteria:\n\n        Patients with any of the following will not be eligible for treatment with Pegasys:\n\n          -  History of neurological disease\n\n          -  History of severe psychiatric disease\n\n          -  Decompensated diabetes\n\n          -  History of immunologically mediated disease\n\n          -  History of severe cardiac disease\n\n          -  History or other evidence of severe chronic pulmonary disease\n\n          -  Inadequate hematologic function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with chronic hepatitis B, and then those who are positive for anti-HDV Ab and\n        treated with Pegasys"
            }
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861444", 
            "org_study_id": "ML25581"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bucharest", 
                    "country": "Romania", 
                    "zip": "022328"
                }
            }
        }, 
        "location_countries": {
            "country": "Romania"
        }, 
        "number_of_groups": "1", 
        "official_title": "National, Multicenter, Observational Study Evaluating Prevalence, Virological and Clinical Characteristics of Chronic Hepatitis Delta in Romania and Assess Efficacy of Peg-interferon Alfa-2a Treatment in Patients With Chronic Hepatitis D (CHD)", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Romania: National Medicines Agency"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Proportion of chronic hepatitis B patients in Romania with chronic hepatitis D infection", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Response rate: Proportion of patients achieving ALT normalization and HDV RNA negativity 24 weeks after the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861444"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Virological characteristics (HBeAg/anti-HBe/HBV DNA/anti-HDV Ab/HDV RNA) of patients with chronic hepatitis D", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }, 
            {
                "measure": "Proportion of chronic hepatitis D patients with liver cirrhosis", 
                "safety_issue": "No", 
                "time_frame": "approximately 3.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}